Virios Therapeutics

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Virios Therapeutics advances Long-COVID treatment, seeks strategic partnerships

Virios Therapeutics is on track with its Long-COVID Phase II study, showing promising results and a clear path towards value creation.
The company's focus on intellectual property protection and partnership development positions it well for long-term growth and innovation in the healthcare sector.
While facing challenges in study outcomes and partnership acquisitions, Virios remains proactive in seizing opportunities to enhance shareholder value and expand its treatment portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

- Continued Progress in Expanding and Advancing Clinical Pipeline - - Conference Call Today at 8:30 a.m. ET -

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that the Food & Drug Administration (“FDA”) communicated that, following their initial review of the Company's chronic toxicology program, the program's studies appear adequate to support the safety of IMC-1 at the dose proposed by the Company for chronic use. With this critical feedback in hand, the Company plans to initiate its proposed pharmacokinetic and food effect study (“pK”) this year, while concurrently resubmitting a final Phase 3 program outline and study protocols for FDA review. Following completion of the pK study, the goal will be to begin enrollment in the first fibromyalgia Phase 3 safety and efficacy study in mid-2024.

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID when treated open-label with a combination of valacyclovir and celecoxib (“Val/Cel”) for 14 weeks, as compared to a control cohort of female Long-COVID patients matched by age, gender and length of illness and treated with routine care. The statistically significant improvements in PASC symptoms and general health status were particularly encouraging given that the mean duration of Long-COVID illness was two years for both the treated and control cohort prior to enrollment in this trial.

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

ATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it has submitted final toxicology reports as per Food & Drug Administration (“FDA”) request as part of their overall review of the Company's Phase 3 proposal.

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Virios Therapeutics (NASDAQ: VIRI ) reported first quarter results for 2023. Virios reported a loss per share of 8 cents.

VIRI Stock Earnings: Virios Beats EPS Estimates

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the first quarter ended March 31, 2023.

Virios Therapeutics Announces First Quarter 2023 Financial Results

ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020.

Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

Virios Therapeutics shares more than doubled after the biotechnology company announced that its proposed Phase 3 program featuring its lead development candidate IMC-1 for fibromyalgia has been considered acceptable based on initial feedback from the US Food and Drug Administration (FDA). IMC-1 is a novel, fixed-dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the company's end goal being the reduction of virally promoted fibromyalgia disease symptoms.

Virios Therapeutics stock doubles as fibromyalgia program moves forward

Virios Therapeutics (NASDAQ: VIRI ) stock is rocketing higher on Tuesday following an update on its planned Phase 3 clinical trial of IMC-1. IMC-1 is Virios Therapeutics' lead drug candidate in development for the treatment of herpes virus replication.

Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?

-Virios' IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results-

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Altamira Therapeutics Ltd

Nektar Therapeutics

Sirius XM Holdings Inc

Penny stocks, the stock market game & what traders are watching this week. The post 4 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch If You're Playing The “Stock Market Game”

CleanSpark

CXApp Inc

Generation Bio

Ferroglobe

PLBY Group

Proterra

SoundHound AI Inc

T2 Biosystems

Virgin Orbit Holdings

Penny stocks to watch this week under $5 The post Best Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 10 To Watch Under $5

ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the fourth quarter and full year ended December 31, 2022.

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), announced today that it will report fourth quarter and full year 2022 financial results on Tuesday, March 14, 2023 before the open of the financial markets.

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that it expects top-line results from its Phase 2 Post-Acute Sequelae of COVID-19 (also known as PASC or Long-COVID) exploratory clinical trial to be available in June 2023. This study will assess the potential of the antiviral combination of valacyclovir and celecoxib to provide symptomatic improvements in patients suffering from Long-COVID when added to standard of care therapy. Outcomes being assessed in this study include fatigue, sleep, attention, pain, autonomic function, memory and anxiety.

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Athenex

Boxed

Penny stocks under $1 to watch this month. The post Penny Stocks To Buy?

Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now

ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) --  Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration (“FDA”) to discuss advancing IMC-1 into Phase 3 development as a treatment for FM has been scheduled for mid-March 2023. At this meeting, the Company will discuss with the FDA plans for a Phase 3 program that would support submission of a new drug application for IMC-1 for the treatment of FM. The Company plans to provide a program update by the end of April following the receipt of formal written feedback from the FDA.

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

ATLANTA--( BUSINESS WIRE )--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Dr. Mike Gendreau - Chief Medical Officer Conference Call Participants Sean Lee - H.C. Wainwright & Co., LLC Operator Good day, and welcome to the Virios Therapeutics, Inc. Q3 Earnings Update.

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript

ATLANTA--( BUSINESS WIRE )--Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development candidate, IMC-1, as a potential new treatment for FM patients.

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets.

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Akero Therapeutics Inc

Astria Therapeutics

HeartBeam

ContraFect

Humanigen

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

Applied DNA Sciences

Avenue Therapeutics

Immuneering Corp

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

News for Virios Therapeutics Stock (VIRI)